Form 4: Zomedica Corp. Director Jeffrey M. Rowe Increases Stake Through Trust

Director Jeffrey M. Rowe increases his indirect holdings in Zomedica Corp. through multiple purchases via a living trust.

Summary

• Jeffrey M. Rowe, a director of Zomedica Corp., has reported changes in his beneficial ownership of the company's common stock.
• On March 17, 2025, Rowe, through the Jeffrey M. Rowe Living Trust, acquired a total of 1,443,995 shares of common stock through multiple transactions at prices ranging from $0.064 to $0.071 per share.
• Following these transactions, the Jeffrey M. Rowe Living Trust beneficially owns 1,714,005 shares.
• Rowe also indirectly owns 11,965,480 shares through other entities, including the M. Rowe Living Trust (664,480 shares), Rowe Family GST (11,120,000 shares), and an IRA (181,000 shares).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's increased investment, suggesting confidence in the company's prospects. However, it's important to consider the size of the investment relative to the director's overall holdings and the company's market capitalization.

Positives

• A director's increased investment in the company may signal confidence in its future prospects.

Industry Context

Insider transactions are closely watched as they can provide insights into management's perspective on the company's valuation and future performance. Increased ownership by a director is often viewed positively.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.

Key Dates